Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymosin alpha1. SciClone Pharmaceuticals.

Andreas Billich1

  • 1Novartis Research Institute, General Dermatology, Vienna, Austria. andreas.billich@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary

Thymosin alpha1 (Talpha1) enhances immune response and is used to treat hepatitis B and C infections. It also shows potential in treating cancers and reducing chemotherapy toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based and Property-Driven Optimization of <i>N</i>-Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors.

Journal of medicinal chemistry·2019
Same author

Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model.

Journal of medicinal chemistry·2018
Same author

Interferon regulatory factor 5 and nuclear factor kappa-B exhibit cooperating but also divergent roles in the regulation of pro-inflammatory cytokines important for the development of TH1 and TH17 responses.

The FEBS journal·2018
Same author

Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.

PloS one·2017
Same author

Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.

Scientific reports·2017
Same author

Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations.

JCI insight·2017

Area of Science:

  • Immunology
  • Pharmacology
  • Hepatology

Background:

  • Thymosin alpha1 (Talpha1) is a synthetic peptide developed for immune response enhancement.
  • It was initially developed for treating hepatitis B virus (HBV) infection and later for hepatitis C virus (HCV) infection.

Purpose of the Study:

  • To summarize the development, therapeutic applications, and regulatory approvals of Thymosin alpha1 (Talpha1).
  • To highlight its role as an immune system enhancer and its potential in treating various diseases.

Main Methods:

  • Review of clinical trial data and regulatory submissions for Talpha1.
  • Analysis of patent filings related to Talpha1 and its analogs.
  • Examination of Talpha1's mechanism of action in potentiating cytokines and reducing drug toxicity.

Main Results:

  • Talpha1 has received approvals in numerous countries for HBV and HCV infections.
  • It is being investigated for non-small cell lung cancer, hepatocellular carcinoma, AIDS, and malignant melanoma.
  • Talpha1 demonstrated efficacy in potentiating cytokines and reducing chemotherapy-induced hematological toxicity.
  • Multiple patents have been granted for Talpha1's use in treating viral infections and cancers.

Conclusions:

  • Thymosin alpha1 (Talpha1) is a versatile immunomodulatory agent with established efficacy in treating viral hepatitis.
  • Its potential applications extend to oncology and as an adjuvant in cancer therapy and vaccination.
  • Ongoing research and patent filings indicate continued development and expansion of Talpha1's therapeutic uses.

Related Experiment Videos